26 November, 2024 in Investor Relations New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
01 November, 2024 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
28 October, 2024 in Investor Relations Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease
22 October, 2024 in Investor Relations Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
17 October, 2024 in Investor Relations New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
14 October, 2024 in Investor Relations Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
05 September, 2024 in Investor Relations Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
29 July, 2024 in Investor Relations, Videos Discover Nexalin’s Neurostimulation Device Targeting Mental Health Disorders
18 July, 2024 in Investor Relations Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
01 July, 2024 in Investor Relations Nexalin Technology Announces Closing of $5.2 Million Public Offering
